Berlin, SANA- Leqembi, an approved drug for the treatment of Alzheimer’s disease, is expected to be officially launched in Germany on September 1st, following Austria’s launch on August 25th , , making them the first EU countries to have access to the therapy.
Austria and Germany are the first two countries in the European Union to launch the drug, which is marketed under the name of Leqembi, according to a statement issued by the Japanese pharmaceutical company, Eisai, and U.S. biotechnology Biogen Inc
This treatment, which was approved after much hesitation, could help a small amount of the approximately one million people with Alzheimer’s in Germany alone. Leqembi, is given intravenously every two weeks ,
Last April, the European Commission approved the drug of Leqembi,which treats early Alzheimer’s disease, specifically the stages of mild cognitive impairment (MCI) or mild dementia.
Noura / Mazen Eyon
